Seeking Alpha

Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham...

Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham analyst who says the recent FDA approval of MelaFind could push the stock as high as $20 over the next year.
Comments (1)
  • jrusso9722
    , contributor
    Comments (98) | Send Message
     
    An entire generation of people will embark on the remainder of their life, with a better chance at life. On the day that MelaFind identifies a non-typical lesion as "cannot rule out Melanoma", the patient will benefit. Early detection saves lives. MelaFind will save lives. MelaFind will help a dermatologist save lives. Because of that, we believe MelaFind will be a success. Because of that success, investors will benefit.
    9 Nov 2011, 06:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs